Form 8-K - Current report:
SEC Accession No. 0001437749-24-022192
Filing Date
2024-07-03
Accepted
2024-07-03 16:46:53
Documents
15
Period of Report
2024-06-28
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbla20240703_8k.htm   iXBRL 8-K 25772
2 EXHIBIT 3.1 ex_695601.htm EX-3.1 8752
  Complete submission text file 0001437749-24-022192.txt   161468

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbla-20240628.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbla-20240628_def.xml EX-101.DEF 10732
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbla-20240628_lab.xml EX-101.LAB 14373
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbla-20240628_pre.xml EX-101.PRE 10782
17 EXTRACTED XBRL INSTANCE DOCUMENT pbla20240703_8k_htm.xml XML 2659
Mailing Address 712 VISTA BLVD #305 WACONIA MN 55387
Business Address 712 VISTA BLVD #305 WACONIA MN 55387 9524791196
Panbela Therapeutics, Inc. (Filer) CIK: 0001029125 (see all company filings)

EIN.: 870543922 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39468 | Film No.: 241100697
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)